Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
Sponsor: UMC Utrecht
Summary
The goal of this clinical trial is to test the beneficial effects of rivastigmine administration, and predict the treatment outcome with electroencephalography (EEG), in patients with severe depression treated with electroconvulsive therapy (ECT). The study has two main objectives: * to study whether rivastigmine would ameliorate the side-effect profile of ECT * to develop an outcome prediction model based on resting state EEG for both the response to treatment as well as its side effect Participants will be assessed by: * Cognitive tests * Questionnaires of clinical symptoms * Questionnaires of depressive symptoms * Bloodsample * Resting state and task-based EEG Researchers will compare patients with a depressive disorder treated with ECT receiving rivastigmine to placebo patches to see if rivastigmine reduces cognitive side effects.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2021-09-29
Completion Date
2026-01
Last Updated
2024-05-10
Healthy Volunteers
No
Conditions
Interventions
Rivastigmine Transdermal Product
The patches will be administered (first four weeks 4.6 mg and then 9.5. mg).
Sham
The sham patches will be administered during the same period of time as the rivastigmine.
Locations (1)
UMC Utrecht
Utrecht, Netherlands